Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HLX 55

Next Previous
Drug Profile

HLX 55

Alternative Names: HLX-55; KTN0216

Latest Information Update: 22 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kolltan Pharmaceuticals
  • Developer Shanghai Henlius Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Dec 2021 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (Shanghai Henlius Biotech pipeline; December 2021)
  • 04 Mar 2020 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (Parenteral, Injection) (NCT04169178)
  • 19 Nov 2019 Henlix (a holding subsidiary of Shanghai Henlius Biotech) plans a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in China and Taiwan (Parenteral) in November 2019 (NCT04169178)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top